Mila Schechtman, M.Sc.

Senior Scientist, Consultant

Ms. Schechtman is the former head of laboratory activities at Neurogenic and was one of the inventors of the schizophrenia immunoassay, along with Dr. Michael Deckmann, in the group of Prof. Meir Shinitzky. An organic chemist by training, Ms. Schechtman successfully completed the technology transfer process from the previous Neurogenic lab in the Weizmann Institute to the company's new facility in Weizmann Science Park, Ness Tziona, the cradle of Israeli biotech. After her retirement from the Weizmann Institute, she continues to be actively involved in the development of the assay in an advisory capacity.

Yechiel Goldman, Ph.D.

Scientific Writer, Consultant

For over 20 years, Dr. Goldman has been working as a regulatory affairs professional in the biotech/pharma sector in Israel. During this period, he has prepared a wide variety of CMC, preclinical, clinical and regulatory documentation for submission to the FDA, EMA and Israeli MoH. He has extensive hands-on experience supporting US/EU/IL product development in oncology, neurology, cellular therapeutics and regenerative medicine.

Yossi Avnat


Mr. Avnat is the CEO of the Wolfson Clore Mayer group of companies for more than 30 years. He earned his B.A. and M.A. degrees in economics from Tel Aviv University and has more than 35 years of managerial experience. He serves as a director in life science companies and as a director in Neurogenic since its inception.

Jonathan D. Leitersdorf

Investor Representative

Mr. Leitersdorf holds a Master of Architecture from the Architectural Association, School of Architecture, London and a Master of Science and Real Estate Development from Columbia University, New York City.

He is a member of the Board of Governors of the Weizmann Institute of Science, Israel.

Mr. Leitersdorf resides in Verbier, Switzerland and has offices in Geneva, Tel-Aviv and New York. He is the representative of the family that is the principal shareholder of Neurogenic Ltd.